Immunic presents positive vidofludimus calcium data at ECTRIMS, showing disability improvement in progressive MS

IMMUNIC, INC.

Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.
Treatment reduced risk of 24-week confirmed disability worsening by 23.8% overall and 33.7% in patients without baseline Gd+ lesions.
Long-term EMPhASIS open-label extension data showed 92.7% of RRMS patients remained free of 24-week confirmed disability worsening at 144 weeks.
Preclinical EAE models demonstrated reduced T cell infiltration and increased neuroprotective markers with vidofludimus calcium.
Data from four poster presentations and one oral presentation highlighted Nurr1 activation as a novel neuroprotective mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.